COMMUNIQUÉS West-GlobeNewswire

Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
01/07/2026
Communiqué de presse Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé La demande d’autorisation de mise sur le [...]
AB Science annonce le succès d’un placement privé de 2,3 millions d’euros
01/07/2026
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE DE 2,3 MILLIONS D’EUROS Paris, 1 er juillet 2026, 8h AB Science S.A. (la “ Société ” ou “ AB Science ”, Euronext – FR0010557264 – AB) annonce [...]
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
01/07/2026
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris PARIS, France, 1 er juillet 2026 – 07h30 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société [...]
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
01/07/2026
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading [...]
Ipsen va acquérir Memo Therapeutics AG, élargissant son portefeuille de maladies rares grâce à l’ajout d’un anticorps premier de sa classe ciblant le polyomavirus BK
01/07/2026
Acquisition centrée sur le potravitug, un anticorps monoclonal premier de sa classe au stade clinique, ciblant le polyomavirus BK L’ensemble des données issues de l’essai de phase II SAFE KIDNEY II soutient le lancement [...]
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01/07/2026
Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III [...]
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
01/07/2026
Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes topline results from [...]
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
01/07/2026
Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug [...]
Eurobio Scientific finalise l'acquisition de la division « Lab Products » de CareDX dédiée à la transplantation
01/07/2026
EUROBIO SCIENTIFIC FINALISE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION Accélération du plan stratégique d’Eurobio visant à devenir un leader du diagnostic moléculaire in vitro [...]
Press Release: Availability of the aide-mémoire for Q2 2026 results
01/07/2026
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026 . Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter [...]
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
01/07/2026
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027; if [...]
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
01/07/2026
SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based [...]
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
01/07/2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License [...]
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
30/06/2026
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides DUBLIN, Ireland and BRIDGEWATER, N. [...]
Acquisition of Own Shares
30/06/2026
Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14
30/06/2026
KIRKLAND, Wash., June 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report fourth quarter fiscal 2026 [...]
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
30/06/2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. [...]
Informations sur le nombre total de droits de vote et d'actions
30/06/2026
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 30 juin 2026, 22h30 CET / 16h30 ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative [...]
CooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure
30/06/2026
SAN RAMON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, released today its 2025 Corporate Sustainability Report. The report showcases the company’s [...]

Pages